LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors

Molecular Neurodegeneration

Volumn 7, Issue 1, 2012, Pages

  Hinkle, Kelly M ^a   Yue, Mei ^a   Behrouz, Bahareh ^a   Dächsel, Justus C ^a   Lincoln, Sarah J ^a   Bowles, Erin E ^a   Beevers, Joel E ^a   Dugger, Brittany ^a   Winner, Beate ^b   Prots, Iryna ^b   Kent, Caroline B ^a   Nishioka, Kenya ^a   Lin, Wen Lang ^a   Dickson, Dennis W ^a   Janus, Christopher J ^c   Farrer, Matthew J ^a,d   Melrose, Heather L ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Autophagy; Dopamine; Kidney; Knockout; Microdialysis; Motor co ordination; Neuropathology; Open field; Parkinsons disease

Indexed keywords

DOPAMINE; LEUCINE RICH REPEAT KINASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC SPINE; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINE UPTAKE; DOPAMINERGIC SYSTEM; EXON; EXPLORATORY BEHAVIOR; FEMALE; GENE MUTATION; KIDNEY; MALE; MOTOR COORDINATION; MOTOR DYSFUNCTION; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; OPEN FIELD TEST; PARKINSON DISEASE; PROTEIN DEGRADATION; ROTAROD TEST;

ANIMALS; AUTOPHAGY; BEHAVIOR, ANIMAL; DOPAMINE; KIDNEY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUTATION; NEURONS; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES;

MUS;

EID: 84861552733     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-7-25     Document Type: Article

References (63)

1. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Zimprich A, et al. Neuron 2004 44 601 607 10.1016/j.neuron.2004.11. 005 15541309 (Pubitemid 39531225)
2. Testing association between LRRK2 and Parkinson's disease and investigating linkage disequilibrium. Paisan-Ruiz C, Evans EW, Jain S, Xiromerisiou G, Gibbs JR, Eerola J, Gourbali V, Hellstrom O, Duckworth J, Papadimitriou A, Tienari PJ, Hadjigeorgiou GM, Singleton AB, J Med Genet 2006 43 9 16467219
3. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, Aasly J, Gibson JM, Ross OA, Lynch T, Wiley J, Payami H, Nutt J, Maraganore DM, Czyzewski K, Styczynska M, Wszolek ZK, Farrer MJ, Toft M, Am J Hum Genet 2005 76 672 680 10.1086/429256 15726496 (Pubitemid 40432174)
4. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M, Hunt AL, Klein C, Henick B, Hailpern SM, Lipton RB, Soto-Valencia J, Risch N, Bressman SB, N Engl J Med 2006 354 424 425 10.1056/NEJMc055509 16436782 (Pubitemid 43145083)
5. Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Ishihara L, et al. Mov Disord 2007 22 55 61 10.1002/mds.21180 17115391 (Pubitemid 46382673)
6. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Di Fonzo A, Wu-Chou YH, Lu CS, van Doeselaar M, Simons EJ, Rohe CF, Chang HC, Chen RS, Weng YH, Vanacore N, Breedveld GJ, Oostra BA, Bonifati V, Neurogenetics 2006 7 133 138 10.1007/s10048-006-0041-5 16633828 (Pubitemid 44078290)
7. Identification of a common genetic risk variant (LRRK2 Gly2385Arg) in Parkinson's disease. Tan EK, Ann Acad Med Singapore 2006 35 840 842 17160203
8. Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. Farrer MJ, Stone JT, Lin CH, Dachsel JC, Hulihan MM, Haugarvoll K, Ross OA, Wu RM, Parkinsonism & related disorders 2007 13 89 92 10.1016/j.parkreldis. 2006.12.001 22921537 (Pubitemid 46329522)
9. Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ross OA, Wu YR, Lee MC, Funayama M, Chen ML, Soto AI, Mata IF, Lee-Chen GJ, Chen CM, Tang M, Zhao Y, Hattori N, Farrer MJ, Tan EK, Wu RM, Ann Neurol 2008 64 88 92 10.1002/ana.21405 18412265
10. On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies. Daniels V, Baekelandt V, Taymans JM, Neurosignals 2011 19 1 15 10.1159/000324488 21430363
11. Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications. Yue Z, Lachenmayer ML, Mov Disord 2011 26 1386 1397 10.1002/mds.23737 21538530
12. Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. Nandhagopal R, Mak E, Schulzer M, McKenzie J, McCormick S, Sossi V, Ruth TJ, Strongosky A, Farrer MJ, Wszolek ZK, Stoessl AJ, Neurology 2008 71 1790 1795 10.1212/01.wnl.0000335973.66333.58 19029519
13. Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. Sossi V, de la Fuente-Fernandez R, Nandhagopal R, Schulzer M, McKenzie J, Ruth TJ, Aasly JO, Farrer MJ, Wszolek ZK, Stoessl JA, Mov Disord 2010 25 2717 2723 10.1002/mds.23356 20939082
14. (123)I-FP-CIT SPET striatal uptake in parkinsonian patients with the alpha-synuclein (G209A) mutation A. Bostantjopoulou S, Katsarou Z, Gerasimou G, Costa DC, Gotzamani-Psarrakou A, Hell J Nucl Med 2008 11 157 159 19081858
15. Positron emission tomography changes in PARK1 mutation. Perani D, Garibotto V, Hadjigeorgiou GM, Papadimitriou D, Fazio F, Papadimitriou A, Mov Disord 2006 21 127 130 10.1002/mds.20691 16211612 (Pubitemid 43273772)
16. PET studies of parkinsonism associated with mutation in the alpha-synuclein gene. Samii A, Markopoulou K, Wszolek ZK, Sossi V, Dobko T, Mak E, Calne DB, Stoessl AJ, Neurology 1999 53 2097 2102 10.1212/WNL.53.9.2097 10599788
17. Dynamic and redundant regulation of LRRK2 and LRRK1 expression. Biskup S, Moore DJ, Rea A, Lorenz-Deperieux B, Coombes CE, Dawson VL, Dawson TM, West AB, BMC Neurosci 2007 8 102 10.1186/1471-2202-8-102 18045479 (Pubitemid 351659657)
18. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Biskup S, Moore DJ, Celsi F, Higashi S, West AB, Andrabi SA, Kurkinen K, Yu SW, Savitt JM, Waldvogel HJ, Faull RL, Emson PC, Torp R, Ottersen OP, Dawson TM, Dawson VL, Ann Neurol 2006 60 557 569 10.1002/ana.21019 17120249 (Pubitemid 44871798)
19. LRRK2 expression linked to dopamine-innervated areas. Galter D, Westerlund M, Carmine A, Lindqvist E, Sydow O, Olson L, Ann Neurol 2006 59 714 719 10.1002/ana.20808 16532471
20. Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Melrose H, Lincoln S, Tyndall G, Dickson D, Farrer M, Neuroscience 2006 139 791 794 10.1016/j.neuroscience.2006.01.017 16504409 (Pubitemid 44308089)
21. LRRK2 is expressed in areas affected by Parkinson's disease in the adult mouse brain. Simon-Sanchez J, Herranz-Perez V, Olucha-Bordonau F, Perez-Tur J, Eur J Neurosci 2006 23 659 666 10.1111/j.1460-9568.2006.04616.x 16487147
22. Distribution of PINK1 and LRRK2 in rat and mouse brain. Taymans JM, Van den Haute C, Baekelandt V, J Neurochem 2006 98 951 961 10.1111/j.1471-4159.2006. 03919.x 16771836 (Pubitemid 44051294)
23. A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Melrose HL, Kent CB, Taylor JP, Dachsel JC, Hinkle KM, Lincoln SJ, Mok SS, Culvenor JG, Masters CL, Tyndall GM, Bass DI, Ahmed Z, Andorfer CA, Ross OA, Wszolek ZK, Delldonne A, Dickson DW, Farrer MJ, Neuroscience 2007 147 1047 1058 10.1016/j.neuroscience.2007.05.027 17611037 (Pubitemid 47102551)
24. Endogenous DA-mediated feedback inhibition of DA neurons: involvement of both D(1)- and D(2)-like receptors. Shi WX, Pun CL, Smith PL, Bunney BS, Synapse 2000 35 111 119 10.1002/(SICI)1098-2396(200002)35:2<111::AID-SYN3>3.0. CO;2-7 10611636 (Pubitemid 30036187)
25. A comparative study of Lrrk2 function in primary neuronal cultures. Dachsel JC, Behrouz B, Yue M, Beevers JE, Melrose HL, Farrer MJ, Parkinsonism Relat Disord 2010 16 650 655 10.1016/j.parkreldis.2010.08.018 20850369
26. Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice. Winner B, Melrose HL, Zhao C, Hinkle KM, Yue M, Kent C, Braithwaite AT, Ogholikhan S, Aigner R, Winkler J, Farrer MJ, Gage FH, Neurobiol Dis 2011 41 706 716 10.1016/j.nbd.2010.12.008 21168496
27. Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. Parisiadou L, Xie C, Cho HJ, Lin X, Gu XL, Long CX, Lobbestael E, Baekelandt V, Taymans JM, Sun L, Cai H, J Neurosci 2009 29 13971 13980 10.1523/JNEUROSCI.3799-09.2009 19890007
28. LRRK2 function on actin and microtubule dynamics in Parkinson disease. Parisiadou L, Cai H, Commun Integr Biol 2010 3 396 400 10.4161/cib.3.5.12286 21057624
29. Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2). Chan D, Citro A, Cordy JM, Shen GC, Wolozin B, J Biol Chem 2011 286 16140 16149 10.1074/jbc.M111.234005 21454543
30. The LRRK2-related Roco kinase Roco2 is regulated by Rab1A and controls the actin cytoskeleton. Kicka S, Shen Z, Annesley SJ, Fisher PR, Lee S, Briggs S, Firtel RA, Mol Biol Cell 2011 22 2198 2211 10.1091/mbc.E10-12-0937 21551065
31. A QUICK screen for Lrrk2 interaction partners-leucine-rich repeat kinase 2 is involved in actin cytoskeleton dynamics. Meixner A, Boldt K, Van Troys M, Askenazi M, Gloeckner CJ, Bauer M, Marto JA, Ampe C, Kinkl N, Ueffing M, Mol Cell Proteomics 2011 10 M110 001172 20876399
32. Methamphetamine-induced structural plasticity in the dorsal striatum. Jedynak JP, Uslaner JM, Esteban JA, Robinson TE, Eur J Neurosci 2007 25 847 853 10.1111/j.1460-9568.2007.05316.x 17328779
33. Doublecortin expression levels in adult brain reflect neurogenesis. Couillard-Despres S, Winner B, Schaubeck S, Aigner R, Vroemen M, Weidner N, Bogdahn U, Winkler J, Kuhn HG, Aigner L, Eur J Neurosci 2005 21 1 14 10.1111/j.1460-9568.2004.03813.x 15654838 (Pubitemid 40193870)
34. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Tong Y, Yamaguchi H, Giaime E, Boyle S, Kopan R, Kelleher RJ, Shen J, Proc Natl Acad Sci U S A 2010 107 9879 9884 10.1073/pnas.1004676107 20457918
35. A Study of the Rat's behavior in a field: A Contribution to Method in Comparative Psychology. Hall C, Ballachey EL, Univ Calif Publ Psych 1932 6 1 12
36. Open-field activity and exploratory behavior. Corman CD, Shafer JN, Psychonomic Science 1968 13 55 56
37. On the construct validity of open-field measures. Royce JR, Psychological Bulletin 1977 84 1098 1106
38. Anxiety disorders in familial parkinsonism. Lauterbach EC, Duvoisin RC, Am J Psychiatry 1991 148 274 1987832
39. Increased risk of developing Parkinson's disease for patients with major affective disorder: a register study. Nilsson FM, Kessing LV, Bolwig TG, Acta Psychiatr Scand 2001 104 380 386 10.1034/j.1600-0447.2001.00372.x 11722320 (Pubitemid 34280555)
40. Non-motor behavioural impairments in parkin-deficient mice. Zhu XR, Maskri L, Herold C, Bader V, Stichel CC, Gunturkun O, Lubbert H, Eur J Neurosci 2007 26 1902 1911 10.1111/j.1460-9568.2007.05812.x 17883413 (Pubitemid 47493196)
41. Thigmotaxis as a test for anxiolytic activity in rats. Pharmacol Biochem Behav 1988 31 959 962 10.1016/0091-3057(88)90413-3 3252289
42. Behavioural phenotyping of transgenic mice. Brown RE, Can J Exp Psychol 2007 61 328 344 18266509
43. LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Herzig MC, Hum Mol Genet 2011 40 4209 4223
44. Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway. Tong Y, Giaime E, Yamaguchi H, Ichimura T, Liu Y, Si H, Cai H, Bonventre JV, Shen J, Mol Neurodegener 2012 7 2 10.1186/1750-1326-7-2 22230652
45. Different data from different labs: lessons from studies of gene-environment interaction. Wahlsten D, Metten P, Phillips TJ, Boehm SL, Burkhart-Kasch S, Dorow J, Doerksen S, Downing C, Fogarty J, Rodd-Henricks K, Hen R, McKinnon CS, Merrill CM, Nolte C, Schalomon M, Schlumbohm JP, Sibert JR, Wenger CD, Dudek BC, Crabbe JC, J Neurobiol 2003 54 283 311 10.1002/neu.10173 12486710 (Pubitemid 36050068)
46. Genetically modified mice and cognition. Lipp HP, Wolfer DP, Curr Opin Neurobiol 1998 8 272 280 10.1016/S0959-4388(98)80151-7 9635213 (Pubitemid 28247811)
47. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Melrose HL, et al. Neurobiol Dis 2010 40 503 517 10.1016/j.nbd.2010.07.010 20659558
48. Motor learning in Ts65Dn mice, a model for Down syndrome. Hyde LA, Crnic LS, Pollock A, Bickford PC, Dev Psychobiol 2001 38 33 45 10.1002/1098-2302(2001) 38:1<33::AID-DEV3>3.0.CO;2-0 11150059 (Pubitemid 32037354)
49. Heregulin, but not ErbB2 or ErbB3, heterozygous mutant mice exhibit hyperactivity in multiple behavioral tasks. Gerlai R, Pisacane P, Erickson S, Behav Brain Res 2000 109 219 227 10.1016/S0166-4328(99)00175-8 10762692 (Pubitemid 30179672)
50. Improved rotorod performance and hyperactivity in mice deficient in a protein repair methyltransferase. Vitali R, Clarke S, Behav Brain Res 2004 153 129 141 10.1016/j.bbr.2003.11.007 15219714 (Pubitemid 38829296)
51. Deletion of the triplet repeat encoding polyglutamine within the mouse Huntington's disease gene results in subtle behavioral/motor phenotypes in vivo and elevated levels of ATP with cellular senescence in vitro. Clabough EB, Zeitlin SO, Hum Mol Genet 2006 15 607 623 10.1093/hmg/ddi477 16403806 (Pubitemid 43205425)
52. Dentate gyrus neurogenesis and depression. Sahay A, Drew MR, Hen R, Prog Brain Res 2007 163 697 722 17765746
53. Adult hippocampal neurogenesis in depression. Sahay A, Hen R, Nat Neurosci 2007 10 1110 1115 10.1038/nn1969 17726477 (Pubitemid 47339960)
54. Targeted disruption of the MHC class II Aa gene in C57BL/6 mice. Kontgen F, Suss G, Stewart C, Steinmetz M, Bluethmann H, Int Immunol 1993 5 957 964 10.1093/intimm/5.8.957 8398989 (Pubitemid 23241767)
55. Paxinos G, Franklin K, The Mouse Brain in Stereotaxic Coordinates Academic, San Diego 2 2001
56. Extended analysis of path data from mutant mice using the public domain software Wintrack. Wolfer DP, Madani R, Valenti P, Lipp HP, Physiol Behav 2001 73 745 753 10.1016/S0031-9384(01)00531-5 11566208 (Pubitemid 32885563)
57. Ethanol's effects on gait dynamics in mice investigated by ventral plane videography. Kale A, Amende I, Meyer GP, Crabbe JC, Hampton TG, Alcohol Clin Exp Res 2004 28 1839 1848 10.1097/01.ALC.0000148103.09378.81 15608600 (Pubitemid 39665200)
58. Gait dynamics in mouse models of Parkinson's disease and Huntington's disease. Amende I, Kale A, McCue S, Glazier S, Morgan JP, Hampton TG, J Neuroeng Rehabil 2005 2 20 10.1186/1743-0003-2-20 16042805 (Pubitemid 41310114)
59. Profiling changes in gait dynamics resulting from progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigrostriatal lesioning. Goldberg NR, Hampton T, McCue S, Kale A, Meshul CK, J Neurosci Res 2011 89 1698 1706 10.1002/jnr.22699 21748776
60. Automated quantitative gait analysis during overground locomotion in the rat: its application to spinal cord contusion and transection injuries. Hamers FP, Lankhorst AJ, van Laar TJ, Veldhuis WB, Gispen WH, J Neurotrauma 2001 18 187 201 10.1089/08977150150502613 11229711 (Pubitemid 32173426)
61. Inhibitory effects of ascorbic acid on dopamine uptake by rat striatal synaptosomes: relationship to lipid peroxidation and oxidation of protein sulfhydryl groups. Morel P, Fauconneau B, Page G, Mirbeau T, Huguet F, Neurosci Res 1998 32 171 179 10.1016/S0168-0102(98)00080-7 9858024 (Pubitemid 29049019)
62. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Bradford MM, Anal Biochem 1976 72 248 254 10.1016/0003-2697(76)90527-3 942051
63. "In vitro" effect of some 5-hydroxy-indolalkylamine derivatives on monoamine uptake system. Moron JA, Perez V, Fernandez-Alvarez E, Marco JL, Unzeta M, J Neural Transm Suppl 1998 52 343 349 9564637